Beam Therapeutics (BEAM) Accounts Payables (2019 - 2026)

Beam Therapeutics (BEAM) has reported Accounts Payables for 8 consecutive years, with $12.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 59.58% year-over-year to $12.3 million; the TTM figure through Mar 2026 stood at $12.3 million (up 59.58% YoY), while the FY2025 annual figure was $10.2 million, up 164.3% from the prior year.
• Accounts Payables advanced to $12.3 million in Q1 2026 per BEAM's latest filing, from $10.2 million in the prior quarter.
• Across five years, Accounts Payables topped out at $14.1 million in Q1 2023 and bottomed at $1.6 million in Q4 2023.
• Historically, Accounts Payables has averaged $7.1 million across 5 years, with a median of $7.0 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables tumbled 82.09% — and 2025, when it jumped 175.95%.
• Beam Therapeutics' Accounts Payables stood at $9.0 million in 2022, then sank by 82.09% to $1.6 million in 2023, then soared by 139.39% to $3.9 million in 2024, then jumped by 164.3% to $10.2 million in 2025, then increased by 20.09% to $12.3 million in 2026.
• Business Quant data shows BEAM's Accounts Payables at $12.3 million in Q1 2026, $10.2 million in Q4 2025, and $9.5 million in Q3 2025.